The demand for Lipid-Lowering Agents in Germany has been on a steady rise in recent years.
Customer preferences: The German market is known for its high demand for quality healthcare products, and the Lipid-Lowering Agents market is no exception. Customers in Germany are increasingly seeking products that are effective in reducing cholesterol levels and have minimal side effects. Additionally, there is a growing preference for natural and organic products, which has led to an increase in demand for plant-based Lipid-Lowering Agents.
Trends in the market: The Lipid-Lowering Agents market in Germany has seen a surge in demand due to the rising prevalence of lifestyle diseases such as obesity, diabetes, and hypertension. As a result, there has been an increase in the number of people diagnosed with high cholesterol levels, leading to a higher demand for Lipid-Lowering Agents. Furthermore, the market has experienced a shift towards combination therapies, where two or more drugs are used to treat high cholesterol levels.
Local special circumstances: Germany has a well-established healthcare system, which has contributed to the growth of the Lipid-Lowering Agents market. The country has a high percentage of elderly citizens, who are more susceptible to lifestyle diseases, leading to an increase in demand for Lipid-Lowering Agents. Additionally, the German government has implemented policies that promote the use of generic drugs, which has made Lipid-Lowering Agents more affordable for the general population.
Underlying macroeconomic factors: The German economy has been stable in recent years, which has contributed to the growth of the Lipid-Lowering Agents market. Additionally, the country has a high level of healthcare spending, which has led to an increase in demand for healthcare products, including Lipid-Lowering Agents. Germany is also home to several pharmaceutical companies that produce Lipid-Lowering Agents, making it easier for customers to access these products.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
